The stock of Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) is a huge mover today! About 1.14 million shares traded hands. Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) has risen 13.56% since April 13, 2016 and is uptrending. It has outperformed by 9.63% the S&P500.
The move comes after 8 months positive chart setup for the $133.09 million company. It was reported on Nov, 15 by Barchart.com. We have $7.45 PT which if reached, will make NASDAQ:AUPH worth $129.10 million more.
According to Zacks Investment Research, “Aurinia Pharmaceuticals Inc. is a late stage biopharmaceutical company. It focuses on the development of therapeutic immunomodulating drug candidate. The company’s lead drug includes Voclosporin for the treatment of lupus nephritis. Aurinia Pharmaceuticals Inc. is headquartered in Victoria, Canada.”
More news for Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) were recently published by: Businesswire.com, which released: “Aurinia Pharmaceuticals to Present at Stifel 2016 Healthcare Conference” on November 10, 2016. Businesswire.com‘s article titled: “Aurinia Establishes At-The-Market Facility” and published on November 09, 2016 is yet another important article.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.